Commercial Adoption - Novocure is driving global active patient growth in Non-Small Cell Lung Cancer (NSCLC) and pursuing reimbursement[1] - NSCLC CE Mark achieved, with launch underway in Germany[1] - NSCLC PMDA approval and launch in Japan[1] - In Q2, there were 121 global NSCLC prescriptions received[8] - 75 unique prescribers prescribed TTFields in Q2[8] - 55% of Q2 prescribers were new to TTFields therapy[8] - 93% of patients prescribed TTFields with ICI were previously treated with ICIs[8] - 76% of patients prescribed TTFields were for 2L or 3L use[8] Clinical Pipeline - PANOVA-3 data presented and published, submitted to FDA, CE Mark and PMDA[1, 13] - METIS submitted to FDA, clinical data published[1] - TRIDENT and PANOVA-4 patient follow up is ongoing, preparing for H1 2026 top-line data[1] Financial Performance - Net revenues for Q2 2025 were $158.8 million, compared to $150.4 million in Q2 2024[15] - Net loss for Q2 2025 was $40.1 million, compared to a net loss of $33.4 million in Q2 2024[15] - Cash, cash equivalents, and investments were $911.5 million[15] - Adjusted EBITDA for the three months ended June 30, 2025, was $(9.9) million, compared to $1.1 million for the same period in 2024[23]

February 2025 Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates NASDAQ:ZLAB | HKEX:9688 © 2025. Zai Lab. All Rights Reserved. Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding o ...